share Stem cell biotech Mesoblast (ASX:MSB) has slashed its quarterly losses as it cut deals in Japan and China, and stepped up from R&D to partnering on its current treatments. The September quarter loss was more than three times lower than in the same period last year, hitting $US5.5m ($8.1m) from $US19.5m ($28.8m). Revenue was up 46 per cent to $17m. Mesoblast, which makes ‘cellular medicines’ for remestemcel-L for conditions such as acute graft versus host disease (GVHD), advanced heart failure and chronic low back pain due to degenerative disc disease, recognised the change came from two areas. The company struck a $US150m deal with German pain management company Grünenthal in September which paid out $US15m that month, for a partnership to develop and commercialise an allogeneic stem cell therapy used to treat chronic low back caused by degenerative disc disease. Royalty revenue on sales of TEMCELL in Japan, […]